{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:28:06Z","timestamp":1774632486769,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":600,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.1164\/rccm.202405-0974ed","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T07:40:42Z","timestamp":1716450042000},"page":"8-9","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":1,"title":["Moving Beyond Antibiotics: Exploring the Potential of an Antivirulence Monoclonal Antibody against\n                    <i>Pseudomonas aeruginosa<\/i>\n                    in Bronchiectasis"],"prefix":"10.1093","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-4418","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Crabb\u00e9","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2026022020490550600_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"2026022020490550600_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026022020490550600_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026022020490550600_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026022020490550600_bib5","doi-asserted-by":"crossref","first-page":"230178","DOI":"10.1183\/16000617.0178-2023","article-title":"Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis","volume":"33","author":"Conceicao","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026022020490550600_bib6","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202308-1403OC","article-title":"A bispecific monoclonal antibody targeting Psl and PcrV enhances neutrophil-mediated killing of Pseudomonas aeruginosa in patients with bronchiectasis","volume":"210","author":"Long","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020490550600_bib7","doi-asserted-by":"crossref","first-page":"e18356","DOI":"10.1371\/journal.pone.0018356","article-title":"Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa","volume":"6","author":"Sato","year":"2011","journal-title":"PLoS One"},{"key":"2026022020490550600_bib8","doi-asserted-by":"crossref","first-page":"e1000354","DOI":"10.1371\/journal.ppat.1000354","article-title":"Assembly and development of the Pseudomonas aeruginosa biofilm matrix","volume":"5","author":"Ma","year":"2009","journal-title":"PLoS Pathog"},{"key":"2026022020490550600_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/thoraxjnl-2021-217576","article-title":"Bacterial biofilms predominate in both acute and chronic human lung infections","volume":"77","author":"Kolpen","year":"2022","journal-title":"Thorax"},{"key":"2026022020490550600_bib10","doi-asserted-by":"crossref","first-page":"262ra155","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa","volume":"6","author":"DiGiandomenico","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026022020490550600_bib11","doi-asserted-by":"crossref","first-page":"629.e1","DOI":"10.1016\/j.cmi.2018.08.004","article-title":"Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults","volume":"25","author":"Ali","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026022020490550600_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-022-04204-9","article-title":"Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial","volume":"26","author":"Chastre","year":"2022","journal-title":"Crit Care"},{"key":"2026022020490550600_bib13","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1128\/JCM.42.11.5229-5237.2004","article-title":"Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis","volume":"42","author":"Jain","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2026022020490550600_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chom.2015.07.006","article-title":"Regional isolation drives bacterial diversification within cystic fibrosis lungs","volume":"18","author":"Jorth","year":"2015","journal-title":"Cell Host Microbe"},{"key":"2026022020490550600_bib15","doi-asserted-by":"crossref","first-page":"2101293","DOI":"10.1183\/13993003.01293-2021","article-title":"Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease","volume":"59","author":"Rigauts","year":"2022","journal-title":"Eur Respir J"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/1\/8\/66997722\/ajrccm_210_1_8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/1\/8\/66997722\/ajrccm_210_1_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:49:14Z","timestamp":1771638554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/210\/1\/8\/8491424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202405-0974ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}